AlphaCrest Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-28,555
| Closed | -$3.03M | – | 745 |
|
|
2022
Q3 | $3.03M | Buy |
28,555
+851
| +3% | +$90.4K | 0.18% | 99 |
|
|
2022
Q2 | $2.7M | Buy |
27,704
+10,304
| +59% | +$1M | 0.13% | 193 |
|
|
2022
Q1 | $1.63M | Sell |
17,400
-14,463
| -45% | -$1.36M | 0.09% | 321 |
|
|
2021
Q4 | $2.71M | Buy |
31,863
+18,016
| +130% | +$1.53M | 0.1% | 272 |
|
|
2021
Q3 | $1.33M | Sell |
13,847
-10,941
| -44% | -$1.05M | 0.07% | 488 |
|
|
2021
Q2 | $2.41M | Buy |
24,788
+13,252
| +115% | +$1.29M | 0.1% | 296 |
|
|
2021
Q1 | $1.12M | Buy |
11,536
+443
| +4% | +$43.1K | 0.06% | 450 |
|
|
2020
Q4 | $1.06M | Buy |
11,093
+2,003
| +22% | +$192K | 0.09% | 298 |
|
|
2020
Q3 | $874K | Buy |
9,090
+7,205
| +382% | +$693K | 0.1% | 311 |
|
|
2020
Q2 | $230K | Sell |
1,885
-10,813
| -85% | -$1.32M | 0.04% | 770 |
|
|
2020
Q1 | $1.1M | Sell |
12,698
-375
| -3% | -$32.5K | 0.13% | 240 |
|
|
2019
Q4 | $1.41M | Sell |
13,073
-398
| -3% | -$42.8K | 0.12% | 206 |
|
|
2019
Q3 | $1.21M | Buy |
13,471
+231
| +2% | +$20.8K | 0.07% | 468 |
|
|
2019
Q2 | $1.12M | Buy |
13,240
+8,086
| +157% | +$683K | 0.1% | 343 |
|
|
2019
Q1 | $454K | Buy |
+5,154
| New | +$454K | 0.07% | 499 |
|